NeuroPointDX, through its sister division Stemina Biomarker Discovery, has developed the leading metabolomics platform for identifying differences in metabolism of patients with ASD and other neurological disorders.

We routinely analyze supernatant from cellular model systems and human samples.  Our team has extensive experience in metabolomics with a specialization in the use of human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells, as well as a variety of cell types resulting from selective differentiation into cells such as neural precursors and a variety of neuronal cell types.

Contact us

learn more about our metabolomics platform technology and expertise in human cellular models

Contact us to learn more about how the power of metabolomics can provide critical information for drug development and clinical trial patient stratification.

(608) 204-0104

504 S. Rosa Rd. Suite 150
Madison, WI 53719

contact@NeuroPointDx.com